Cell Therapeutics Seeks EU Approval

Cell Therapeutics (NASDAQ: CTIC), the Seattle-based developer of cancer drugs, said today it has filed an application for approval to start selling a new lymphoma drug in the European Union. The company is asking the European Medicines Agency to allow sales of pixantrone (Pixuvri) to adult patients with relapsed forms of non-Hodgkin’s lymphoma. The company’s application for U.S. approval was turned down by the FDA in April.

Trending on Xconomy